TY  - JOUR 
AU  - Iannantuoni, Francesca
AU  - M. de Marañon, Aranzazu
AU  - Díaz Morales, Noelia
AU  - Falcon, Rosa
AU  - Bañuls, Celia
AU  - Abad-Jimenez, Zaida
AU  - Victor, Victor M.
AU  - Hernandez-Mijares, Antonio
AU  - Rovira-Llopis, Susana
PY  - 2019
UR  - http://hdl.handle.net/10366/169708
AB  - [EN]Sodium-glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise molecular mechanisms are still elusive. We aimed to evaluate the...
LA  - spa
PB  - MDPI
KW  - Empagliflozina (Inhibidor de SGLT2)
KW  - Diabetes tipo 2
KW  - Inflamación
KW  - Estrés oxidativo
KW  - Leucocitos
KW  - Respuesta antioxidante
KW  - Empagliflozin (SGLT2 inhibitor)
KW  - Type 2 diabetes
KW  - Inflammation
KW  - Oxidative stress
KW  - Leukocytes
KW  - Antioxidant response
KW  - Diabetes Mellitus, Type 2
KW  - Oxidative Stress
KW  - Inflammation
KW  - Leukocytes
TI  - The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
DO  - 10.3390/jcm8111814
T2  - Journal of Clinical Medicine
VL  - 8
M2  - 1814
ER  -